4D Molecular Therapeutics (FDMT) Other Non-Current Liabilities (2019 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Other Non-Current Liabilities of $121000.0 for Q1 2026, down 31.64% year-over-year from $177000.0 in Q1 2025, and down 12.32% quarter-over-quarter from $138000.0 in Q4 2025.
Powered by 
Analysis
4D Molecular Therapeutics (FDMT) Other Non-Current Liabilities (2019 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Other Non-Current Liabilities for 8 consecutive years, with $121000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 31.64% year-over-year to $121000.0; the TTM figure through Mar 2026 stood at $121000.0 (down 31.64% YoY), while the FY2025 annual figure was $138000.0, down 28.5% from the prior year.
- Other Non-Current Liabilities fell to $121000.0 in Q1 2026 per FDMT's latest filing, from $138000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $369000.0 in Q4 2023 and bottomed at $12000.0 in Q2 2022.
- Historically, Other Non-Current Liabilities has averaged $134647.1 across 5 years, with a median of $138000.0 in 2025.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities tumbled 99.36% — and 2023, when it surged 1657.14%.
- 4D Molecular Therapeutics' Other Non-Current Liabilities stood at $21000.0 in 2022, then soared by 1657.14% to $369000.0 in 2023, then tumbled by 47.7% to $193000.0 in 2024, then decreased by 28.5% to $138000.0 in 2025, then declined by 12.32% to $121000.0 in 2026.
- Business Quant data shows FDMT's Other Non-Current Liabilities at $121000.0 in Q1 2026, $138000.0 in Q4 2025, and $345000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | 4D Molecular Therapeutics | 1.05 Bn | 692.04 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 384,000.00 |
| Mar 31, 2026 | 370,000.00 |
| Dec 31, 2025 | 358,000.00 |
| Sep 30, 2025 | 345,000.00 |
| Jun 30, 2025 | 334,000.00 |
| Mar 31, 2025 | 322,000.00 |
| Dec 31, 2024 | 410,000.00 |
| Sep 30, 2024 | 396,000.00 |
| Jun 30, 2024 | 382,000.00 |
| Mar 31, 2024 | 369,000.00 |
| Dec 31, 2023 | 369,000.00 |
| Sep 30, 2023 | 369,000.00 |
| Jun 30, 2023 | 212,000.00 |
| Mar 31, 2023 | 219,000.00 |
| Dec 31, 2022 | 212,000.00 |
| Sep 30, 2022 | 213,000.00 |
| Jun 30, 2022 | 222,000.00 |
| Mar 31, 2022 | 221,000.00 |
| Dec 31, 2021 | 214,000.00 |
| Sep 30, 2021 | 1.89 Mn |